Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance

被引:34
|
作者
Mazumder, Sonia [1 ]
Higgins, Paul J. [1 ]
Samarakoon, Rohan [1 ]
机构
[1] Albany Med Coll, Dept Regenerat & Canc Cell Biol, Albany, NY 12208 USA
关键词
ccRCC; HIF-alpha; VHL; EGFR; MET; HYPOXIA-INDUCIBLE FACTOR; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; TYPE-1; MATRIX-METALLOPROTEINASE; CLINICAL-PRACTICE GUIDELINES; VONHIPPEL-LINDAU DISEASE; CYCLIN D1 EXPRESSION; C-MYC; INTERFERON-ALPHA; FACTOR RECEPTOR;
D O I
10.3390/cancers15041316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clear cell variant of renal cell carcinoma (ccRCC) is the most common renal epithelial malignancy and responsible for most of the deaths from kidney cancer. Patients carrying inactivating mutations in the Von Hippel-Lindau (VHL) gene have an increased proclivity to develop several types of tumors including ccRCC. Normally, the Hypoxia Inducible Factor alpha (HIF-alpha) subunits of the HIF heterodimeric transcription factor complex are regulated by oxygen-dependent prolylhydroxylation, VHL-mediated ubiquitination and proteasomal degradation. Loss of pVHL function results in elevated levels of HIF-alpha due to increased stability, leading to RCC progression. While HIF-1 alpha acts as a tumor suppressor, HIF-2 alpha promotes oncogenic potential by driving tumor progression and metastasis through activation of hypoxia-sensitive signaling pathways and overexpression of HIF-2 alpha target genes. One strategy to suppress ccRCC aggressiveness is directed at inhibition of HIF-2 alpha and the associated molecular pathways leading to cell proliferation, angiogenesis, and metastasis. Indeed, clinical and pre-clinical data demonstrated the effectiveness of HIF-2 alpha targeted therapy in attenuating ccRCC progression. This review focuses on the signaling pathways and the involved genes (cyclin D, c-Myc, VEGF-a, EGFR, TGF-alpha, GLUT-1) that confer oncogenic potential downstream of the VHL-HIF-2 alpha signaling axis in ccRCC. Discussed as well are current treatment options (including receptor tyrosine kinase inhibitors such as sunitinib), the medical challenges (high prevalence of metastasis at the time of diagnosis, refractory nature of advanced disease to current treatment options), scientific challenges and future directions.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status
    Tumkur Sitaram, Raviprakash
    Landstrom, Marene
    Roos, Goran
    Ljungberg, Borje
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (04) : 216 - 222
  • [32] Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma
    Hsieh, James J.
    Le, Valerie H.
    Oyama, Toshinao
    Ricketts, Christopher J.
    Thai Huu Ho
    Cheng, Emily H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (36) : 3533 - +
  • [33] Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α
    Fan, Yang
    Li, Hongzhao
    Ma, Xin
    Gao, Yu
    Bao, Xu
    Du, Qingshan
    Ma, Minghui
    Liu, Kan
    Yao, Yuanxin
    Huang, Qingbo
    Zhang, Yu
    Zhang, Xu
    ONCOTARGET, 2016, 7 (14) : 18280 - 18294
  • [34] VHL mutations are associated with increased expression of VHL and ubiquitin in clear cell renal cell carcinoma.
    Hughson, M
    He, Z
    Liu, S
    Shingleton, WB
    LABORATORY INVESTIGATION, 2001, 81 (01) : 111A - 111A
  • [35] VHL mutations are associated with increased expression of VHL and ubiquitin in clear cell renal cell carcinoma.
    Hughson, M
    He, Z
    Liu, S
    Shingleton, WB
    MODERN PATHOLOGY, 2001, 14 (01) : 111A - 111A
  • [36] Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells
    Malec, Viktor
    Coulson, Judy M.
    Urbe, Sylvie
    Clague, Michael J.
    JOURNAL OF PROTEOME RESEARCH, 2015, 14 (12) : 5263 - 5272
  • [37] Antigenic targets in clear cell renal cell carcinoma
    Schindler, Nicholas R.
    Braun, David A.
    KIDNEY CANCER, 2023, 7 (01) : 81 - 91
  • [38] Emerging Targets in Clear Cell Renal Cell Carcinoma
    Chen, Yu-Wei
    Rini, Brian, I
    Beckermann, Kathryn E.
    CANCERS, 2022, 14 (19)
  • [39] Allicin inhibits human renal clear cell carcinoma progression via suppressing HIF pathway
    Song, Bin
    Shu, Ying
    Cui, Tianlei
    Fu, Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (11): : 20573 - 20580
  • [40] Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
    Hu, Junhui
    Tan, Ping
    Ishihara, Moe
    Bayley, Nicholas A.
    Schokrpur, Shiruyeh
    Reynoso, Jeremy G.
    Zhang, Yangjun
    Lim, Raymond J.
    Dumitras, Camelia
    Yang, Lu
    Dubinett, Steven M.
    Jat, Parmjit S.
    Van Snick, Jacques
    Huang, Jiaoti
    Chin, Arnold I.
    Prins, Robert M.
    Graeber, Thomas G.
    Xu, Hua
    Wu, Lily
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)